AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3158325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31270591 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based patient-specific instruments (PSI)
Number of subjects: 124
Study 31270591 — intervention group
Group type: COMPARATOR
Intervention: MRI-based patient-specific instruments (PSI)
Number of subjects: 124
Study 30325453 — intervention group
Group type: EXPERIMENTAL
Intervention: PreKT
Number of subjects: 1138
Study 30325453 — intervention group
Group type: COMPARATOR
Intervention: DiaKT
Number of subjects: 1138
Study 28687670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone PVI
Number of subjects: 118
Study 28687670 — intervention group
Group type: COMPARATOR
Intervention: PVI plus Substrate modification
Number of subjects: 118
Study 25945935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radio frequency treatment
Number of subjects: 20
Study 24286801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of cultured MSCs with hyaluronic acid 3 weeks after surgery
Number of subjects: 56
Study 24286801 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 56
Study 21519084 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbert screw fixation
Number of subjects: 33
Study 21519084 — intervention group
Group type: EXPERIMENTAL
Intervention: Matti Russe bone grafting
Number of subjects: 33
Study 21519084 — intervention group
Group type: EXPERIMENTAL
Intervention: Kohlman modification of vascularised muscle pedicle graft procedure
Number of subjects: 33
Study 21519084 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 33
Study 18641189 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA mixture (trans-10, cis-12 conjugated linoleic acid)
Number of subjects: 75
Study 18641189 — intervention group
Group type: COMPARATOR
Intervention: CLA milk (cis-9, trans-11 conjugated linoleic acid)
Number of subjects: 75
Study 18641189 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 75
Study 17061710 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided customized corneal LASIK (CATz)
Number of subjects: 23
Study 17061710 — intervention group
Group type: COMPARATOR
Intervention: Conventional LASIK (NAVEX)
Number of subjects: 23
Study 14534919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 0
Study 14534919 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BR)
Number of subjects: 0
Study 14534919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10920064 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided stent deployment
Number of subjects: 525
Study 10920064 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance alone
Number of subjects: 525
Study 8848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated tone in a tone sequence
Number of subjects: 0
Study 8848258 — intervention group
Group type: COMPARATOR
Intervention: Mismatch negativity
Number of subjects: 0
Study 1411403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tetracycline, ornidazole, bismuth subcitrate)
Number of subjects: 10
Study 1411403 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole/bismuth subcitrate (O/CBS)
Number of subjects: 10
Study 1411403 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐urea breath test
Number of subjects: 10
Study 1411403 — intervention group
Group type: EXPERIMENTAL
Intervention: HP serology
Number of subjects: 10
Study 1411403 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-stimulated gastrin release
Number of subjects: 10
Study 3931154 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (centrally active anticholinergic drug) administered in three different intravenous doses
Number of subjects: 10
Study 3931154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30723098 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group-based healthy eating and physical activity intervention
Number of subjects: 60
Study 30723098 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 29566206 — intervention group
Group type: EXPERIMENTAL
Intervention: Actissist (digital health intervention delivered via smartphone app over 12 weeks)
Number of subjects: 36
Study 29566206 — intervention group
Group type: EXPERIMENTAL
Intervention: Actissist
Number of subjects: 36
Study 27720984 — intervention group
Group type: EXPERIMENTAL
Intervention: IPI (interactive photo interface)
Number of subjects: 108
Study 27720984 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI (sketching-based interface)
Number of subjects: 108
Study 27720984 — intervention group
Group type: COMPARATOR
Intervention: TLP (traditional life-size photo)
Number of subjects: 108
Study 27720984 — intervention group
Group type: EXPERIMENTAL
Intervention: IPI
Number of subjects: 108
Study 27720984 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI
Number of subjects: 108
Study 24435411 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 945
Study 24435411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Navigation Intervention (TNI)
Number of subjects: 945
Study 24435411 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 945
Study 23131879 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 37
Study 23131879 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 37
Study 19891620 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell treatment for cardiac repair
Number of subjects: 0
Study 17627698 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany/Resilon (experimental)
Number of subjects: 60
Study 17627698 — intervention group
Group type: COMPARATOR
Intervention: gutta‐percha/AH Plus (control)
Number of subjects: 60
Study 17627698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform (used in both groups)
Number of subjects: 60
Study 13680074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 96
Study 13680074 — intervention group
Group type: EXPERIMENTAL
Intervention: Current MDMA users
Number of subjects: 96
Study 13680074 — intervention group
Group type: COMPARATOR
Intervention: Non-MDMA substance users
Number of subjects: 96
Study 13680074 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait aggression
Number of subjects: 96
Study 13680074 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 96
Study 11355477 — intervention group
Group type: EXPERIMENTAL
Intervention: Videorentgenocinematographic examinations after partial laryngectomy
Number of subjects: 81
Study 11355477 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of defects in a part of the base of the tongue with a vascular pedicle flap of the submandibular gland
Number of subjects: 81
Study 11355477 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 subjects)
Number of subjects: 81
Study 9391668 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (middle ear pressure changes)
Number of subjects: 39
Study 9391668 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study 8430715 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic therapy with dialyzable leukocyte extract
Number of subjects: 90
Study 8430715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 90
Study 8430715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immunologic therapy and CBT
Number of subjects: 90
Study 8430715 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific treatment regimens
Number of subjects: 90
Study 3318897 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg twice daily
Number of subjects: 49
Study 3318897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30798674 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment supporters providing medical and social support to PLWHA
Number of subjects: 25
Study 30798674 — intervention group
Group type: EXPERIMENTAL
Intervention: Open communication and committed emotional support from treatment supporters
Number of subjects: 25
Study 30798674 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and systemic support for treatment supporters
Number of subjects: 25
Study 30798674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of HIV-related knowledge among treatment supporters
Number of subjects: 25
Study 30115112 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-help metacognitive therapy (Home-MCT) plus usual cardiac rehabilitation
Number of subjects: 108
Study 30115112 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation
Number of subjects: 108
Study 26735552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 20
Study 26735552 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 20
Study 24411003 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg plus ezetimibe
Number of subjects: 0
Study 24411003 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 0
Study 24411003 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 0
Study 22278986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of strong motivation for physical activity
Number of subjects: 176
Study 22278986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of strong beliefs related to physical activity
Number of subjects: 176
Study 20814815 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus enzastaurin (1,250 mg/m² twice daily plus 500 mg/day)
Number of subjects: 85
Study 20814815 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus placebo
Number of subjects: 85
Study 20814815 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus enzastaurin
Number of subjects: 85
Study 17551305 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 on day 1 and day 8 every 3 weeks for 6 cycles)
Number of subjects: 40
Study 15867552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection (CSI)
Number of subjects: 132
Study 15867552 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 132
Study 15867552 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized stretching program only)
Number of subjects: 132
Study 11935098 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 126
Study 11935098 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular endurance training
Number of subjects: 126
Study 11935098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination training
Number of subjects: 126
Study 11935098 — intervention group
Group type: COMPARATOR
Intervention: Non-training reference group
Number of subjects: 126
Study 10487482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet for 3 months
Number of subjects: 53
Study 10487482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet
Number of subjects: 53
Study 10487482 — intervention group
Group type: COMPARATOR
Intervention: Matched responders (10)
Number of subjects: 53
Study 8726539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (up to 5 mg daily)
Number of subjects: 13
Study 8726539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8726539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (10 mg daily in open-label phase)
Number of subjects: 13
Study 8726539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (higher doses)
Number of subjects: 13
Study 1762811 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of a mannitol solution containing 7.5 mg/kg L‐tryptophan
Number of subjects: 45
Study 1762811 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of a mannitol solution containing 15 mg/kg L‐tryptophan
Number of subjects: 45
Study 1762811 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of 5% mannitol solution i.v.
Number of subjects: 45
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 100 mg/day
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg/day
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 400 mg/day
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 600 mg/day
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (various doses)
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day) with amenorrhea
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up in infertile patients
Number of subjects: 27
Study 6210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of infertile patients who conceived vs. did not conceive
Number of subjects: 27
Study 31621845 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 191
Study 31621845 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching cartoons
Number of subjects: 191
Study 31621845 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 191
Study 28817342 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 68
Study 28817342 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 68
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid 1 mg (single dose)
Number of subjects: 48
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid 1 mg (repeated doses for 7 days)
Number of subjects: 48
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid 4 mg (single dose under fed conditions)
Number of subjects: 48
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid (various doses 1, 2, and 4 mg)
Number of subjects: 48
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid (general findings)
Number of subjects: 48
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid (food effect)
Number of subjects: 48
Study 25748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid (age effect)
Number of subjects: 48
Study 25675570 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated needle therapy at Tiantu (CV 22)
Number of subjects: 71
Study 25675570 — intervention group
Group type: COMPARATOR
Intervention: Regular needle therapy at Tiantu (CV 22)
Number of subjects: 71
Study 20864611 — intervention group
Group type: EXPERIMENTAL
Intervention: LET'S intervention (n=178)
Number of subjects: 352
Study 20864611 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=174)
Number of subjects: 352
Study 18363059 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 75
Study 18363059 — intervention group
Group type: COMPARATOR
Intervention: Non-TEA
Number of subjects: 75
Study 17543140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (LAC) 500 mg, 2 capsules/day plus 500 mg i.m. injection for 2 weeks, then 3 capsules/day for 8 weeks
Number of subjects: 102
Study 17543140 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 capsules/day plus placebo i.m. injection for 2 weeks, then placebo for 8 weeks
Number of subjects: 102
Study 17543140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (LAC)
Number of subjects: 102
Study 14749760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water fortified with folic acid (563 microg/day), vitamins B(6) (1 mg/day), B(12) (7.5 microg/day), cholecalciferol (0.6 microg/day), and calcium (563 mg/day)
Number of subjects: 66
Study 14749760 — intervention group
Group type: COMPARATOR
Intervention: Placebo mineral water
Number of subjects: 66
Study 10604327 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber diet
Number of subjects: 14
Study 10604327 — intervention group
Group type: COMPARATOR
Intervention: Insoluble fiber diet
Number of subjects: 14
Study 9362599 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based education program
Number of subjects: 100
Study 9362599 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 1606348 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous ciprofloxacin
Number of subjects: 0
Study 1606348 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg intravenous ciprofloxacin
Number of subjects: 0
Study 1606348 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg intravenous ciprofloxacin
Number of subjects: 0
Study 4003485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic solution (670 ml Osmol)
Number of subjects: 20
Study 4003485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic solution (224 ml Osmol)
Number of subjects: 20
Study 4003485 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 20
Study 3591898 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraperm O2 lenses
Number of subjects: 6
Study 3591898 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston II lenses
Number of subjects: 6
Study 28929521 — intervention group
Group type: COMPARATOR
Intervention: Radavirsen 0.5 mg kg-1 to 8 mg kg-1 (single ascending doses)
Number of subjects: 56
Study 28929521 — intervention group
Group type: COMPARATOR
Intervention: Radavirsen 8 mg kg-1 (multiple doses)
Number of subjects: 56
Study 28929521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single ascending doses)
Number of subjects: 56
Study 28929521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple doses)
Number of subjects: 56
Study 28069045 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard feedback strategy
Number of subjects: 203
Study 28069045 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted feedback strategy
Number of subjects: 203
Study 28069045 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed feedback strategy
Number of subjects: 203
Study 26024304 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 209
Study 26024304 — intervention group
Group type: EXPERIMENTAL
Intervention: repaglinide
Number of subjects: 209
Study 23074151 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during pPCI
Number of subjects: 3235
Study 23074151 — intervention group
Group type: COMPARATOR
Intervention: No thrombus aspiration (TA) during pPCI
Number of subjects: 3235
Study 21080920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 315
Study 21080920 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 315
Study 21080920 — intervention group
Group type: COMPARATOR
Intervention: 0.125% Bupivacaine
Number of subjects: 315
Study 18226760 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-based outreach intervention
Number of subjects: 158
Study 16446748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Monitoring System (TMS) - participants weighed themselves daily and received feedback on weight changes via email.
Number of subjects: 0
Study 16446748 — intervention group
Group type: COMPARATOR
Intervention: Control group - participants were weighed at the beginning and the end of the semester without daily monitoring.
Number of subjects: 0
Study 12972470 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris Hip Score
Number of subjects: 75
Study 12972470 — intervention group
Group type: COMPARATOR
Intervention: Walking speed
Number of subjects: 75
Study 12972470 — intervention group
Group type: COMPARATOR
Intervention: Pain during walking
Number of subjects: 75
Study 12972470 — intervention group
Group type: COMPARATOR
Intervention: SF-36 bodily pain
Number of subjects: 75
Study 12972470 — intervention group
Group type: COMPARATOR
Intervention: SF-36 physical functioning
Number of subjects: 75
Study 11005266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) 0.5 mg twice weekly
Number of subjects: 20
Study 11005266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (QUI) 75 microg once daily
Number of subjects: 20
Study 11005266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11005266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB)
Number of subjects: 20
Study 11005266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (QUI)
Number of subjects: 20
Study 9172129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent auditory input in children
Number of subjects: 0
Study 9172129 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent auditory input in children
Number of subjects: 0
Study 9172129 — intervention group
Group type: COMPARATOR
Intervention: Auditory N100 responses in adults
Number of subjects: 0
Study 1287833 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (25 mg/min, max dose 15 mg/kg)
Number of subjects: 30
Study 1287833 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.75-1.0 mg intravenously according to renal function and body weight)
Number of subjects: 30
Study 3920066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) with lactose powder
Number of subjects: 15
Study 3920066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) in micropellets without lactose
Number of subjects: 15
Study 3920066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) solution
Number of subjects: 15
Study 31757216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine filter cohort (0.2/1.2 μm filters, n=1506)
Number of subjects: 3012
Study 31757216 — intervention group
Group type: COMPARATOR
Intervention: Control filter cohort (5.0 μm filters, n=1506)
Number of subjects: 3012
Study 29771807 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotonic glucose-sodium hydration solution for 40 days postdischarge
Number of subjects: 80